146 related articles for article (PubMed ID: 18708629)
1. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome.
Wechalekar AD; Lachmann HJ; Goodman HJ; Bradwell A; Hawkins PN; Gillmore JD
Blood; 2008 Nov; 112(10):4009-16. PubMed ID: 18708629
[TBL] [Abstract][Full Text] [Related]
2. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
3. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity.
Palladini G; Russo P; Bosoni T; Sarais G; Lavatelli F; Foli A; Bragotti LZ; Perfetti V; Obici L; Bergesio F; Albertini R; Moratti R; Merlini G
Clin Lymphoma Myeloma; 2009 Mar; 9(1):80-3. PubMed ID: 19362981
[TBL] [Abstract][Full Text] [Related]
4. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN
Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348
[TBL] [Abstract][Full Text] [Related]
5. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
Dispenzieri A; Lacy MQ; Katzmann JA; Rajkumar SV; Abraham RS; Hayman SR; Kumar SK; Clark R; Kyle RA; Litzow MR; Inwards DJ; Ansell SM; Micallef IM; Porrata LF; Elliott MA; Johnston PB; Greipp PR; Witzig TE; Zeldenrust SR; Russell SJ; Gastineau D; Gertz MA
Blood; 2006 Apr; 107(8):3378-83. PubMed ID: 16397135
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.
Bochtler T; Hegenbart U; Heiss C; Benner A; Cremer F; Volkmann M; Ludwig J; Perz JB; Ho AD; Goldschmidt H; Schonland SO
Haematologica; 2008 Mar; 93(3):459-62. PubMed ID: 18287137
[TBL] [Abstract][Full Text] [Related]
7. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.
Terrier B; Jaccard A; Harousseau JL; Delarue R; Tournilhac O; Hunault-Berger M; Hamidou M; Dantal J; Bernard M; Grosbois B; Morel P; Coiteux V; Gisserot O; Rodon P; Hot A; Elie C; Leblond V; Fermand JP; Fakhouri F
Medicine (Baltimore); 2008 Mar; 87(2):99-109. PubMed ID: 18344807
[TBL] [Abstract][Full Text] [Related]
8. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Milani P; Basset M; Russo F; Foli A; Merlini G; Palladini G
Blood; 2017 Aug; 130(5):625-631. PubMed ID: 28546143
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
[TBL] [Abstract][Full Text] [Related]
10. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia.
Gertz MA; Kyle RA; Noel P
J Clin Oncol; 1993 May; 11(5):914-20. PubMed ID: 8487054
[TBL] [Abstract][Full Text] [Related]
11. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
12. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
13. Clinical presentation and treatment responses in IgM-related AL amyloidosis.
Sissoko M; Sanchorawala V; Seldin D; Sworder B; Angelino K; Broce M; Berk J; Sloan JM
Amyloid; 2015; 22(4):229-35. PubMed ID: 26488936
[TBL] [Abstract][Full Text] [Related]
14. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.
Dittrich T; Bochtler T; Kimmich C; Becker N; Jauch A; Goldschmidt H; Ho AD; Hegenbart U; Schönland SO
Blood; 2017 Aug; 130(5):632-642. PubMed ID: 28550043
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
Sanchorawala V; Wright DG; Rosenzweig M; Finn KT; Fennessey S; Zeldis JB; Skinner M; Seldin DC
Blood; 2007 Jan; 109(2):492-6. PubMed ID: 16960148
[TBL] [Abstract][Full Text] [Related]
16. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
17. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.
Weiss BM; Hebreo J; Cordaro DV; Roschewski MJ; Baker TP; Abbott KC; Olson SW
J Clin Oncol; 2014 Sep; 32(25):2699-704. PubMed ID: 25024082
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.
Seldin DC; Choufani EB; Dember LM; Wiesman JF; Berk JL; Falk RH; O'Hara C; Fennessey S; Finn KT; Wright DG; Skinner M; Sanchorawala V
Clin Lymphoma; 2003 Mar; 3(4):241-6. PubMed ID: 12672274
[TBL] [Abstract][Full Text] [Related]
19. Amyloidosis with IgM monoclonal gammopathies.
Gertz MA; Kyle RA
Semin Oncol; 2003 Apr; 30(2):325-8. PubMed ID: 12720162
[TBL] [Abstract][Full Text] [Related]
20. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
